Vivek Subbiah, MD, on RET Fusion–Positive Cancers: Efficacy of Selpercatinib

April 12, 2021 By The ASCO Post Staff

Vivek Subbiah, MD, of The University of Texas MD Anderson Cancer Center, discusses data on selpercatinib that showed promising activity across a variety of RET fusion–positive cancers, including treatment-refractory gastrointestinal malignancies. This analysis highlights the need for genomic profiling to identify actionable oncogenic drivers.

Related Content